封面
市場調查報告書
商品編碼
2174931

分子傳染病檢查市場:全球市場預測,2026-2032年

Molecular Infectious Disease Testing Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,分子傳染病檢查市場將成長至 193.4 億美元,複合年成長率為 10.77%。

主要市場統計數據
基準年 2025 94.4億美元
預計年份:2026年 104.3億美元
預測年份 2032 193.4億美元
複合年成長率 (%) 10.77%

分子傳染病檢查:概述

分子傳染病檢查利用核酸技術,包括聚合酵素鏈鎖反應(PCR) 和其他擴增方法,來檢測病原體或病原體特異性遺傳物質。當快速、高靈敏度和標靶診斷能夠指導治療、感染控制決策、檢查室和公共衛生應對措施時,其臨床價值最為顯著。此領域涵蓋醫院、實驗室、診所和分散式醫療感染疾病感染疾病呼吸道、消化器官系統、性行為感染傳播、血液傳播、醫療相關和新興感染疾病。

從集中診斷到協調分散的醫療服務。

當前趨勢正從集中式檢查室工作流程轉向整合式診斷網路,將高通量平台與患者就近檢測和即時檢測相結合。多重檢測板支援鑑別診斷,而自動化、互聯互通和標準化工作流程則提高了操作的一致性。推動這一趨勢的因素還包括對抗生素抗藥性監測、疫情防控、檢查室容量、保險報銷規定、採購慣例以及在不同檢體類型和醫療環境中保持檢測性能的需求。

透過人工智慧 (AI) 增強結果解讀和工作流程管理

人工智慧(AI)可透過結果解讀、品管監控、異常檢測、檢查室排程以及將檢測結果與臨床和流行病學資訊整合,為分子傳染病檢查做出貢獻。其實際效用取決於代表性的訓練資料、透明的檢驗、網路安全、人工監督以及對錯誤或不確定輸出的明確課責。人工智慧最有效的方式是輔助合格的實驗室技術人員和臨床醫生的判斷,而不是取代分析檢驗或既定的生物安全程序。

區域洞察:能力差異與通用準備重點

在北美,重點在於快速診斷、檢查室自動化、抗生素抗藥性監測以及與電子健康記錄(EHR)的整合。在歐洲,健全的檢查室網路與監管要求和跨境數據需求相結合。亞太地區情況差異很大,既有先進的都市區檢查室系統,也有在進入、物流和人才取得方面仍有瓶頸的地區。在拉丁美洲,分散式存取、監測和可靠的供應鏈仍然是優先事項。在中東,專科醫院和參考檢查室的能力建設正在推進,而在非洲,重點是擴大檢測範圍、檢體運輸、人才培養以及發展疫情應對基礎設施。

集團洞察:貿易、監管與安全推動採用

在東協市場,鑑於檢測設施成熟度、採購系統和監管協調程度往往存在差異,互通性和區域應對能力至關重要。金磚國家成員國的公共衛生優先事項和國內生產能力各不相同,因此在獲取途徑和應對能力方面的合作至關重要。歐盟優先考慮監管協調、監測和跨境健康資料交換。七國集團(G7)國家普遍優先考慮先進診斷技術、生物安全和創新管治。海灣合作理事會(GCC)國家正在加強集中式和以醫院為基礎的系統,而北約成員國則更加重視衛生安全、互通性和應對生物威脅的準備工作。

各國概況:關鍵檢測系統的不同優先事項

澳洲優先考慮地域分散的醫療服務取得、監測和檢查室品質。巴西正在努力平衡廣泛的公共衛生需求與區域性醫療服務取得挑戰。加拿大優先發展聯網的公共衛生檢查室和遠距醫療服務,而中國則持續擴大診斷能力並整合數位醫療。法國、德國、義大利、西班牙和英國的重點是檢查室品質、抗菌素抗藥性、緊急準備和協調的醫療服務。印度正努力將大規模的診斷需求與擴大醫療服務取得和加強國家能力的努力結合。日本和韓國優先考慮自動化、品管系統和快速反應。墨西哥持續致力於解決區域性醫療服務取得差異和監測需求。俄羅斯的優先事項包括國家級實驗室能力和感染疾病監測。美國則專注於先進的分子檢測流程、分散式檢查、與醫療保健的整合以及公共衛生緊急準備。

領導者行動指南:建構具有韌性和臨床整合的實驗室網路

行業領導者應使其檢測組合與明確的臨床和公共衛生應用場景相匹配,在相關人群和檢體集中檢驗其性能,並設計可在集中式和分散式環境下運行的工作流程。投資應優先考慮互通性、網路安全、品管、人才培養、供應鏈韌性和透明的證據產生。部署人工智慧的組織應建立管治,監測不同人口統計和地理群體中的效能,保持人工審核,並記錄模型變更。與實驗室、臨床醫生、公共衛生機構和採購部門建立夥伴關係將有助於推廣應用,並確保檢測結果能夠為適當的治療和監測決策做出貢獻。

調查方法:基於證據的分子檢測趨勢評估。

本執行摘要是基於所提供的市場定義以及必要的區域和經濟分組建構而成。報告整合了分子診斷領域中已確立的、有數據支撐的主題,包括技術發展、檢查室運作、臨床效用、公共衛生監測、法規、基礎設施和數位整合。區域、分組和國家層級的說明相對定性,避免了市場估算、預測、市場佔有率、展望以及未經證實的公司特定聲明。結論應結合現行監管指南、同儕審查的證據、檢查室標準和相關司法管轄區的公共衛生數據進行解讀。

結論:可靠的分子檢測取決於整合與信任。

分子傳染病檢查正成為現代診斷、監測和緊急準備的核心要素。其優勢不僅取決於檢測的靈敏度和平台的速度,還取決於合理的臨床應用、便捷的基礎設施、檢驗的工作流程、熟練的人員、安全的資料交換以及穩健的供應鏈。最有效的長期策略是將檢查室創新與公共衛生優先事項結合,同時謹慎利用人工智慧,保持科學透明度,並堅持專家監督。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章 分子傳染病檢查市場:依產品類型分類

  • 裝置
  • 試劑和試劑盒
  • 軟體和服務

第8章 分子傳染病檢查市場:依技術分類

  • DNA微陣列
  • DNA定序與次世代定序
  • 原位雜合反應
  • 恒溫核酸增幅技術
  • 聚合酵素鏈鎖反應

第9章 分子傳染病檢查市場:依病原體類型分類

  • 細菌
  • 真菌
  • 寄生蟲
  • 病毒性的

第10章 分子傳染病檢查市場:依檢體類型分類

  • 血
  • 呼吸系統
  • 航班
  • 尿

第11章 分子傳染病檢查市場:依應用領域分類

  • 診斷測試
  • 流行病學調查
  • 篩檢測試
  • 治療監測

第12章 分子傳染病檢查市場:依最終用戶分類

  • 診斷檢查室
  • 醫院和診所
  • 研究機構

第13章 分子傳染病檢查市場:依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 分子傳染病檢查市場:依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 分子傳染病檢查市場:依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第17章:公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Altona Diagnostics GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioFire Diagnostics, LLC
  • bioMerieux SA
  • Cepheid by Danaher Corporation
  • Eurofins Viracor LLC
  • F. Hoffmann-La Roche Ltd
  • GenScript Biotech Corporation
  • Grifols SA
  • Hologic Inc.
  • Illumina, Inc.
  • Luminex Corporation
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novacyt Group
  • PerkinElmer, Inc.
  • Qiagen NV
  • QuidelOrtho Corporation
  • Seegene Inc.
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

第18章 主要專家

Product Code: MRR-FF5E5BF3B455

The Molecular Infectious Disease Testing Market is projected to grow by USD 19.34 billion at a CAGR of 10.77% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.44 billion
Estimated Year [2026] USD 10.43 billion
Forecast Year [2032] USD 19.34 billion
CAGR (%) 10.77%

Molecular Infectious Disease Testing: Executive Overview

Molecular infectious disease testing uses nucleic-acid technologies, including polymerase chain reaction and other amplification methods, to detect pathogens or pathogen-specific genetic material. Its clinical value is strongest where rapid, sensitive, and targeted diagnosis can guide treatment, infection-control decisions, surveillance, and public-health response. The field spans respiratory, gastrointestinal, sexually transmitted, blood-borne, healthcare-associated, and emerging infections across hospitals, laboratories, clinics, and decentralized care settings.

From Centralized Diagnosis to Connected, Decentralized Care

The landscape is shifting from centralized laboratory workflows toward integrated diagnostic networks that combine high-throughput platforms with near-patient and point-of-care testing. Multiplex panels can support differential diagnosis, while automation, connectivity, and standardized workflows improve operational consistency. Adoption is also shaped by antimicrobial-resistance surveillance, outbreak preparedness, laboratory capacity, reimbursement rules, procurement practices, and the need to maintain performance across varied specimen types and care environments.

Artificial Intelligence Strengthens Interpretation and Workflow Management

Artificial intelligence can contribute to molecular infectious disease testing through result interpretation, quality-control monitoring, anomaly detection, laboratory scheduling, and integration of test results with clinical and epidemiological information. Its practical impact depends on representative training data, transparent validation, cybersecurity, human oversight, and clear accountability for incorrect or uncertain outputs. AI is most useful when it augments qualified laboratory and clinical judgment rather than replacing analytical validation or established biosafety procedures.

Regional Insights: Uneven Capacity, Shared Preparedness Priorities

North America emphasizes rapid diagnostics, laboratory automation, antimicrobial-resistance monitoring, and integration with electronic health records. Europe combines strong laboratory networks with regulatory and cross-border data requirements. Asia-Pacific presents substantial diversity, ranging from advanced urban laboratory systems to settings where access, logistics, and workforce availability remain constraints. Latin America continues to prioritize decentralized access, surveillance, and dependable supply chains. The Middle East is strengthening specialized hospital and reference-laboratory capacity, while Africa focuses on expanding testing access, specimen transport, workforce capability, and outbreak-response infrastructure.

Group Insights: Trade, Regulation, and Security Shape Adoption

ASEAN markets commonly face differences in laboratory maturity, procurement systems, and regulatory alignment, making interoperability and regional preparedness important. BRICS members reflect varied public-health priorities and domestic manufacturing capabilities, with collaboration relevant to access and resilience. The European Union emphasizes harmonized regulation, surveillance, and cross-border health-data exchange. G7 countries generally prioritize advanced diagnostics, biosecurity, and innovation governance. GCC countries are strengthening centralized and hospital-based capacity, while NATO members place additional emphasis on health security, interoperability, and readiness for biological threats.

Country Insights: Diverse Priorities Across Major Testing Systems

Australia emphasizes geographically distributed access, surveillance, and laboratory quality; Brazil balances broad public-health needs with regional access challenges. Canada prioritizes networked public-health laboratories and remote-service delivery, while China continues expanding diagnostic capacity and digital health integration. France, Germany, Italy, Spain, and the United Kingdom focus on laboratory quality, antimicrobial resistance, preparedness, and coordinated healthcare delivery. India combines large-scale diagnostic demand with efforts to widen access and strengthen domestic capacity. Japan and South Korea emphasize automation, quality systems, and rapid response. Mexico continues to address uneven regional access and surveillance needs. Russia's priorities include national laboratory capability and infectious-disease monitoring. The United States focuses on advanced molecular workflows, decentralized testing, healthcare integration, and public-health preparedness.

Actions for Leaders: Build Resilient, Clinically Integrated Testing Networks

Industry leaders should align assay portfolios with clearly defined clinical and public-health use cases, validate performance across relevant populations and specimens, and design workflows for both centralized and decentralized settings. Investments should prioritize interoperability, cybersecurity, quality management, workforce training, supply-chain resilience, and transparent evidence generation. Organizations adopting AI should establish governance, monitor performance across demographic and geographic groups, preserve human review, and document model changes. Partnerships with laboratories, clinicians, public-health agencies, and procurement authorities can improve implementation and ensure that testing contributes to appropriate treatment and surveillance decisions.

Research Methodology: Evidence-Based Assessment of Molecular Testing Dynamics

This executive summary is structured around the supplied market definition and the required geographic and economic groupings. It synthesizes established, data-backed themes in molecular diagnostics, including technology development, laboratory operations, clinical utility, public-health surveillance, regulation, infrastructure, and digital integration. Regional, group, and country narratives are comparative and qualitative; they avoid market estimates, market shares, forecasts, and unsupported company-specific claims. Conclusions should be interpreted alongside current regulatory guidance, peer-reviewed evidence, laboratory standards, and jurisdiction-specific public-health data.

Conclusion: Reliable Molecular Testing Depends on Integration and Trust

Molecular infectious disease testing is becoming a core component of modern diagnosis, surveillance, and preparedness. Its benefits depend not only on assay sensitivity or platform speed, but also on appropriate clinical use, accessible infrastructure, validated workflows, skilled personnel, secure data exchange, and resilient supply chains. The strongest long-term strategies will connect laboratory innovation with public-health priorities while applying AI cautiously, maintaining scientific transparency, and preserving expert oversight.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Molecular Infectious Disease Testing Market, by Product Type

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Kits
  • 7.4. Software & Services

8. Molecular Infectious Disease Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. DNA Microarrays
  • 8.3. DNA Sequencing & Next-Generation Sequencing
  • 8.4. In Situ Hybridization
  • 8.5. Isothermal Nucleic Acid Amplification Technology
  • 8.6. Polymerase Chain Reaction

9. Molecular Infectious Disease Testing Market, by Pathogen Type

  • 9.1. Introduction
  • 9.2. Bacterial
  • 9.3. Fungal
  • 9.4. Parasitic
  • 9.5. Viral

10. Molecular Infectious Disease Testing Market, by Specimen Type

  • 10.1. Introduction
  • 10.2. Blood
  • 10.3. Respiratory
  • 10.4. Stool
  • 10.5. Urine

11. Molecular Infectious Disease Testing Market, by Application

  • 11.1. Introduction
  • 11.2. Diagnostic Testing
  • 11.3. Epidemiological Investigations
  • 11.4. Screening Testing
  • 11.5. Therapeutic Monitoring

12. Molecular Infectious Disease Testing Market, by End Users

  • 12.1. Introduction
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics
  • 12.4. Research Institutes

13. Molecular Infectious Disease Testing Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Molecular Infectious Disease Testing Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Molecular Infectious Disease Testing Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Agilent Technologies, Inc.
  • 17.3. Altona Diagnostics GmbH
  • 17.4. Becton, Dickinson and Company
  • 17.5. Bio-Rad Laboratories, Inc.
  • 17.6. BioFire Diagnostics, LLC
  • 17.7. bioMerieux SA
  • 17.8. Cepheid by Danaher Corporation
  • 17.9. Eurofins Viracor LLC
  • 17.10. F. Hoffmann-La Roche Ltd
  • 17.11. GenScript Biotech Corporation
  • 17.12. Grifols S.A.
  • 17.13. Hologic Inc.
  • 17.14. Illumina, Inc.
  • 17.15. Luminex Corporation
  • 17.16. Merck KGaA
  • 17.17. Myriad Genetics, Inc.
  • 17.18. Novacyt Group
  • 17.19. PerkinElmer, Inc.
  • 17.20. Qiagen N.V.
  • 17.21. QuidelOrtho Corporation
  • 17.22. Seegene Inc.
  • 17.23. Siemens Healthineers
  • 17.24. Sysmex Corporation
  • 17.25. Thermo Fisher Scientific, Inc.

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Molecular Infectious Disease Testing Market, Years Considered for the Study
  • FIGURE 2. Global Molecular Infectious Disease Testing Market, Research Design
  • FIGURE 3. Global Molecular Infectious Disease Testing Market, Research Framework
  • FIGURE 4. Global Molecular Infectious Disease Testing Market, Data Triangulation
  • FIGURE 5. Global Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Molecular Infectious Disease Testing Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Molecular Infectious Disease Testing Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Molecular Infectious Disease Testing Market Size, by Technology, 2025 vs 2032 (%)
  • FIGURE 9. Global Molecular Infectious Disease Testing Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2025 vs 2032 (%)
  • FIGURE 11. Global Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Molecular Infectious Disease Testing Market Size, by Specimen Type, 2025 vs 2032 (%)
  • FIGURE 13. Global Molecular Infectious Disease Testing Market Size, by Specimen Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Molecular Infectious Disease Testing Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 15. Global Molecular Infectious Disease Testing Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Molecular Infectious Disease Testing Market Size, by End Users, 2025 vs 2032 (%)
  • FIGURE 17. Global Molecular Infectious Disease Testing Market Size, by End Users, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Molecular Infectious Disease Testing Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Molecular Infectious Disease Testing Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Molecular Infectious Disease Testing Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Molecular Infectious Disease Testing Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Molecular Infectious Disease Testing Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Molecular Infectious Disease Testing Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Molecular Infectious Disease Testing Market Segmentation & Coverage
  • TABLE 2. Global Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Reagents & Kits Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Reagents & Kits Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Reagents & Kits Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Software & Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Software & Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Software & Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 14. Global DNA Microarrays Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global DNA Microarrays Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global DNA Microarrays Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global DNA Sequencing & Next-Generation Sequencing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global DNA Sequencing & Next-Generation Sequencing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global DNA Sequencing & Next-Generation Sequencing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global In Situ Hybridization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global In Situ Hybridization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global In Situ Hybridization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Isothermal Nucleic Acid Amplification Technology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Isothermal Nucleic Acid Amplification Technology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Isothermal Nucleic Acid Amplification Technology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Polymerase Chain Reaction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Polymerase Chain Reaction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Polymerase Chain Reaction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 30. Global Bacterial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Bacterial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Bacterial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Fungal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Fungal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Fungal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Parasitic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Parasitic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Parasitic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Viral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Viral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Viral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 43. Global Blood Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Blood Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Blood Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Respiratory Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Respiratory Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Respiratory Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Stool Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Stool Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Stool Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Urine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Urine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Urine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 56. Global Diagnostic Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Diagnostic Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Diagnostic Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Epidemiological Investigations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Epidemiological Investigations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Epidemiological Investigations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Screening Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Screening Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Screening Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Therapeutic Monitoring Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Therapeutic Monitoring Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Therapeutic Monitoring Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 69. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Molecular Infectious Disease Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Asia-Pacific Molecular Infectious Disease Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Asia-Pacific Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 81. Asia-Pacific Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 82. Asia-Pacific Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 83. Asia-Pacific Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 84. Asia-Pacific Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 85. Asia-Pacific Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 86. North America Molecular Infectious Disease Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. North America Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 88. North America Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 89. North America Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 90. North America Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 91. North America Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 92. North America Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 93. Latin America Molecular Infectious Disease Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Latin America Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 95. Latin America Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 96. Latin America Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 97. Latin America Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 98. Latin America Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 99. Latin America Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 100. Europe Molecular Infectious Disease Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Europe Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 102. Europe Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 103. Europe Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 104. Europe Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 105. Europe Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 106. Europe Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 107. Middle East Molecular Infectious Disease Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Middle East Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 109. Middle East Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 110. Middle East Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 111. Middle East Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 112. Middle East Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 113. Middle East Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 114. Africa Molecular Infectious Disease Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Africa Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 116. Africa Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 117. Africa Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 118. Africa Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 119. Africa Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 120. Africa Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 121. Global Molecular Infectious Disease Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 122. ASEAN Molecular Infectious Disease Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. ASEAN Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 124. ASEAN Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 125. ASEAN Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 126. ASEAN Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 127. ASEAN Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 128. ASEAN Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 129. GCC Molecular Infectious Disease Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 130. GCC Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 131. GCC Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 132. GCC Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 133. GCC Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 134. GCC Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 135. GCC Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 136. European Union Molecular Infectious Disease Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. European Union Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 138. European Union Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 139. European Union Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 140. European Union Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 141. European Union Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 142. European Union Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 143. BRICS Molecular Infectious Disease Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. BRICS Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 145. BRICS Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 146. BRICS Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 147. BRICS Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 148. BRICS Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 149. BRICS Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 150. G7 Molecular Infectious Disease Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 151. G7 Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 152. G7 Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 153. G7 Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 154. G7 Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 155. G7 Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 156. G7 Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 157. NATO Molecular Infectious Disease Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 158. NATO Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 159. NATO Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 160. NATO Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 161. NATO Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 162. NATO Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 163. NATO Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 164. Global Molecular Infectious Disease Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 165. United States Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 166. United States Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 167. United States Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 168. United States Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 169. United States Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 170. United States Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 171. United States Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 172. Canada Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 173. Canada Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 174. Canada Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 175. Canada Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 176. Canada Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 177. Canada Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 178. Canada Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 179. Mexico Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 180. Mexico Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 181. Mexico Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 182. Mexico Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 183. Mexico Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 184. Mexico Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 185. Mexico Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 186. Brazil Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 187. Brazil Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 188. Brazil Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 189. Brazil Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 190. Brazil Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 191. Brazil Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 192. Brazil Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 193. United Kingdom Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 194. United Kingdom Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 195. United Kingdom Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 196. United Kingdom Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 197. United Kingdom Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 198. United Kingdom Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 199. United Kingdom Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 200. Germany Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 201. Germany Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 202. Germany Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 203. Germany Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 204. Germany Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 205. Germany Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 206. Germany Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 207. France Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 208. France Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 209. France Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 210. France Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 211. France Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 212. France Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 213. France Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 214. Russia Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 215. Russia Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 216. Russia Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 217. Russia Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 218. Russia Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 219. Russia Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 220. Russia Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 221. Italy Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 222. Italy Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 223. Italy Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 224. Italy Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 225. Italy Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 226. Italy Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 227. Italy Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 228. Spain Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 229. Spain Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 230. Spain Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 231. Spain Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 232. Spain Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 233. Spain Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 234. Spain Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 235. China Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 236. China Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 237. China Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 238. China Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 239. China Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 240. China Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 241. China Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 242. India Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 243. India Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 244. India Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 245. India Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 246. India Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 247. India Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 248. India Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 249. Japan Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 250. Japan Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 251. Japan Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 252. Japan Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 253. Japan Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 254. Japan Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 255. Japan Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 256. Australia Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 257. Australia Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 258. Australia Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 259. Australia Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 260. Australia Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 261. Australia Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 262. Australia Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 263. South Korea Molecular Infectious Disease Testing Market Size, 2017-2032 (USD Million)
  • TABLE 264. South Korea Molecular Infectious Disease Testing Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 265. South Korea Molecular Infectious Disease Testing Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 266. South Korea Molecular Infectious Disease Testing Market Size, by Pathogen Type, 2017-2032 (USD Million)
  • TABLE 267. South Korea Molecular Infectious Disease Testing Market Size, by Specimen Type, 2017-2032 (USD Million)
  • TABLE 268. South Korea Molecular Infectious Disease Testing Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 269. South Korea Molecular Infectious Disease Testing Market Size, by End Users, 2017-2032 (USD Million)
  • TABLE 270. Global Molecular Infectious Disease Testing Market Share, by Key Player, 2025
  • TABLE 271. Global Molecular Infectious Disease Testing Market, Key Experts